[junkie-button url=”https://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
MyoVista® hsECG™ Utilizes Wavelet Technology to Detect Cardiac Diastolic Dysfunction
HeartSciences announced today the commercial launch of its MyoVista® high sensitivity electrocardiograph (hsECG™) Testing Device in the Middle East. The MyoVista hsECG is now available for commercial sale in the first markets of United Arab Emirates (UAE) and Kuwait and will soon extend to other countries in the region.
The MyoVista hsECG was developed using Continuous Wavelet Transform mathematics and goes beyond conventional ECG technology with new metrics to detect repolarization abnormalities according to the company. HeartSciences reportst this new capability enables physicians to detect diastolic dysfunction which is typically diagnosed using tissue Doppler echocardiography. As an early manifestation of many types of heart disease, diastolic dysfunction has become a significant area of interest in cardiology. Coronary artery disease (CAD), hypertrophy, cardiomyopathy and valvular diseases are examples of diseases that will cause diastolic dysfunction.
The MyoVista hsECG, incorporates all of the capabilities of a full featured 12-lead resting ECG plus new proprietary informatics that assist in detecting diastolic dysfunction. Using machine learning, MyoVista hsECG technology detected diastolic dysfunction with 88 percent sensitivity, and 87 percent specificity, in a recent clinical trial at Mount Sinai Hospital in New York.*
Chief Executive Officer Mark Hilz commented, “The MyoVista hsECG represents an exciting breakthrough in ECG technology.” Hilz went on to say, “We look forward to introducing this breakthrough technology to the Gulf region.”
In the region, MyoVista will be sold via distribution partners. The device is also available across the European Union, where it received the CE (Conformité Européenne) Mark approval earlier this year. HeartSciences is also in the process of expanding distribution to Canada, Australia, Latin America and Asia-Pacific. HeartSciences expects to seek U.S. Food and Drug Administration clearance for MyoVista in 2018.
*Data on file at HeartSciences